Yorktown Management & Research Co Inc acquired a new stake in Inogen, Inc (NASDAQ:INGN) during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 4,050 shares of the medical technology company’s stock, valued at approximately $385,000.
Several other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Inogen by 1.9% in the second quarter. BlackRock Inc. now owns 2,150,552 shares of the medical technology company’s stock valued at $205,207,000 after purchasing an additional 39,752 shares during the last quarter. Vanguard Group Inc. raised its holdings in shares of Inogen by 24.9% in the second quarter. Vanguard Group Inc. now owns 1,515,342 shares of the medical technology company’s stock valued at $144,594,000 after purchasing an additional 301,737 shares during the last quarter. Koch Industries Inc. raised its holdings in shares of Inogen by 19,485.8% in the second quarter. Koch Industries Inc. now owns 657,102 shares of the medical technology company’s stock valued at $650,000 after purchasing an additional 653,747 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Inogen by 3.4% in the second quarter. Dimensional Fund Advisors LP now owns 519,523 shares of the medical technology company’s stock valued at $49,572,000 after purchasing an additional 17,111 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Inogen by 6.8% in the second quarter. State Street Corp now owns 425,662 shares of the medical technology company’s stock valued at $40,619,000 after purchasing an additional 27,250 shares during the last quarter.
A number of brokerages recently weighed in on INGN. Zacks Investment Research upgraded shares of Inogen from a “hold” rating to a “buy” rating and set a $131.00 target price on the stock in a report on Thursday, November 9th. BidaskClub downgraded shares of Inogen from a “buy” rating to a “hold” rating in a report on Tuesday. Leerink Swann restated an “outperform” rating and set a $120.00 target price (up from $115.00) on shares of Inogen in a report on Wednesday, November 8th. Piper Jaffray Companies restated a “hold” rating and set a $90.00 target price on shares of Inogen in a report on Tuesday, September 12th. Finally, Needham & Company LLC boosted their target price on shares of Inogen from $108.00 to $125.00 and gave the stock a “strong-buy” rating in a report on Wednesday, November 8th. Four research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Inogen currently has an average rating of “Buy” and a consensus target price of $103.14.
In other Inogen news, Director Raymond Huggenberger sold 14,000 shares of the company’s stock in a transaction on Friday, September 15th. The shares were sold at an average price of $102.30, for a total value of $1,432,200.00. Following the transaction, the director now directly owns 7,808 shares in the company, valued at $798,758.40. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, EVP Matt Scribner sold 2,500 shares of the company’s stock in a transaction on Monday, September 11th. The shares were sold at an average price of $103.23, for a total transaction of $258,075.00. Following the completion of the transaction, the executive vice president now owns 6,964 shares in the company, valued at $718,893.72. The disclosure for this sale can be found here. Over the last quarter, insiders sold 88,000 shares of company stock worth $9,349,730. Corporate insiders own 5.31% of the company’s stock.
Shares of Inogen, Inc (NASDAQ:INGN) traded down $1.14 on Thursday, reaching $116.29. 157,088 shares of the company were exchanged, compared to its average volume of 171,499. Inogen, Inc has a fifty-two week low of $62.69 and a fifty-two week high of $130.05. The firm has a market capitalization of $2,469.17, a P/E ratio of 96.19, a price-to-earnings-growth ratio of 4.97 and a beta of 1.13.
Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, November 7th. The medical technology company reported $0.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.29 by $0.04. Inogen had a net margin of 11.36% and a return on equity of 13.37%. The firm had revenue of $69.00 million for the quarter, compared to the consensus estimate of $63.55 million. During the same period in the previous year, the company earned $0.25 earnings per share. The company’s quarterly revenue was up 26.8% on a year-over-year basis. analysts anticipate that Inogen, Inc will post 1.19 EPS for the current year.
COPYRIGHT VIOLATION NOTICE: “Yorktown Management & Research Co Inc Invests $385,000 in Inogen, Inc (INGN)” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this news story on another publication, it was stolen and reposted in violation of United States & international copyright laws. The original version of this news story can be accessed at https://www.dispatchtribunal.com/2017/12/08/yorktown-management-research-co-inc-acquires-new-position-in-inogen-inc-ingn.html.
Inogen, Inc is a medical technology company. The Company develops, manufactures and markets portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The Company’s Inogen One systems concentrate the air around the patient to offer a single source of supplemental oxygen anytime, anywhere with a portable device.
Receive News & Ratings for Inogen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen Inc and related companies with MarketBeat.com's FREE daily email newsletter.